Search tips
Search criteria 


Logo of aapspharmspringer.comThis journalToc AlertsSubmit OnlineOpen Choice
AAPS PharmSciTech. 2003 March; 4(1): 62–70.
Published online 2003 February 3. doi:  10.1208/pt040109
PMCID: PMC2750305

Artificial neural networks in the modeling and optimization of aspirin extended release tablets with eudragit L 100 as matrix substance


The purpose of the present study was to model the effects of the concentration of Eudragit L 100 and compression pressure as the most important process and formulation variables on the in vitro release profile of aspirin from matrix tables formulated with Eudragit L 100 as matrix substance and to optimize the formulation by artificial neural network. As model formulations, 10 kinds of aspirin matrix tablets were prepared. The amount of Eudragit L 100 and the compression pressure were selected as causal factors. In vitro dissolution time profiles at 4 different sampling times were chosen as responses. A set of release parameters and causal factors were used as tutorial data for the generalized regression neural, network (GRNN) and analyzed using a computer. Observed results of drug release studies indicate that drug release rates vary widely between investigated formulations, with a range of 5 hours to more than 10 hours to complete dissolution. The GRNN model was optimized. The root mean square value for the trained network was 1.12%, which indicated that the optimal GRNN model was reached. Applying the generalized distance function method, the optimal tablet formulation predicted by GRNN was with 5% of Eudragit L 100 and tablet hardness 60N. Calculated difference (f1 2.465) and similarity (f2 85.61) factors indicate that there is no difference between predicted and experimentally observed drug release profiles for the optimal formulation. This work illustrates the potential for an artificial neural network, GRNN, to assist in development of extended release dosage forms.

Keywords: artificial neural network, matrix tablets, controlled release, Eudragit L 100, aspirin

Full Text

The Full Text of this article is available as a PDF (120K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
1. Takayama K, Fujikawa M, Nagai T. Artificial neural networks as a novel method to optimize pharmaceutical formulations. Pharm Res. 1999;16(1):1–6. [PubMed]
2. Takahara J, Takayama K, Nagai T. Multi-objective simultaneous optimization technique based on an artificial neural, network in sustained release formulations. J Control Release. 1997;49:11–20. doi: 10.1016/S0168-3659(97)00030-8. [Cross Ref]
3. Kesavan JG, Peck GE. Pharmaceutical granulation and tablet formulation using neural networks. Pharm Dev Technol. 1996;1(4):391–404. doi: 10.3109/10837459609031434. [PubMed] [Cross Ref]
4. Wu T, Pan W, Chen J, Zhang R. Formulation optimization technique based on artificial neural network in salbutamol sulfate osmotic pump tablets. Drug Dev Ind Pharm. 2000;26(2):211–215. doi: 10.1081/DDC-100100347. [PubMed] [Cross Ref]
5. Chen Y, McCall TW, Baichwal AR, Meyer MC. The application of an artificial neural network and pharmacokinetic simulations in the design of controlled-release dosage fomrs. J Control Release. 1999;59:33–41. doi: 10.1016/S0168-3659(98)00171-0. [PubMed] [Cross Ref]
6. Bourquin J, Schmidli H, Hoogevest P, Leuenberger H. Application of artificial neural networks (ANN) in the development of solid dosage forms. Pharm Dev Technol. 1997;2(2):111–121. doi: 10.3109/10837459709022616. [PubMed] [Cross Ref]
7. Bourquin J, Schmidli H, Hoogevest P, Leuenberger H. Advantages of artificial neural networks (ANNs) as alternative modelling technique for data sets showing non-linear relationships using data from a galenical study on a solid dosage form. Eur J Pharm Sci. 1998;7:5–16. doi: 10.1016/S0928-0987(97)10028-8. [PubMed] [Cross Ref]
8. Bourquin J, Schmidli H, Hoogevest P, Leuenberger H. Pitfalls of artificial neural networks (ANN) modelling technique for data sets containing outlier measurements using a study on mixture properties of a direct compressed dosage form. Eur J Pharm Sci. 1998;7:17–28. doi: 10.1016/S0928-0987(97)10027-6. [PubMed] [Cross Ref]
9. Achanta AS, Kowalski JG, Rhodes CT. Artificial neural networks: implications for pharmaceutical sciences. Drug Dev Ind Pharm. 1995;21(1):119–155. doi: 10.3109/03639049509048099. [Cross Ref]
10. Takka S, Rajbhandari S, Sakr A. Effect of anionic polymers on the release of propranolol hydrochloride from matrix tablets. Eur J Pharm Sci. 2001;52:75–82. [PubMed]
11. Rekhi GS, Nellore RV, Hussain AS, Tillmean LG, Malinowski HJ, Ausburger LL. Identification of critical formulation and processing variables for metoprolol tartarate extended release tablets. J Control Release. 1999;59:327–342. doi: 10.1016/S0168-3659(99)00004-8. [PubMed] [Cross Ref]
12. Jovanović M, Jovičić G, Durić Z, Agbaba D, Karlijković-Rajic K, Radovanović J, Nikolic L. Effect of fillers and lubricants on acetylsalicylic acid release kinetics from Eudragit matrix tablets. Drug Dev Ind Pharm. 1997;23:595–602. doi: 10.3109/03639049709149825. [Cross Ref]
13. Jovanović M, Jovičić G, Durić Z, Agbaba D, Karljiković-Rajic K, Nikolić L, Radovanović J. The influence of Eudragit type on the dissolution rate of acetylsalicylic acid from matrix tablets. Acta Pharm Hung. 1997;67:229–234. [PubMed]
14. Speckt DF. A generalized regression neural network. IEEE Trans Neural Networks. 1991;2(6):568–576. doi: 10.1109/72.97934. [PubMed] [Cross Ref]
15. Patterson D. Artificial Neural Networks. Singapore: Prentice Hall; 1996.
16. Bishop C. Neural Networks for Pattern Recognition. Oxford, England: Oxford University Press; 1995.
17. Manual of STATISTICA Neural Networks Software. Tulsa, OK: StatSoft, Inc; 1998.
18. Khuri I, Conlon M. Simultaneous optimization of multiple responses represented by polynomial regression functions. Technometrics. 1981;23:363–375. doi: 10.2307/1268226. [Cross Ref]
19. Dissolution Testing of Immediate Release Solid Oral Dosage Forms. Rockville, MD: Center for Drug Evaluation and Research; 1997.

Articles from AAPS PharmSciTech are provided here courtesy of American Association of Pharmaceutical Scientists